Insider Transactions in Q1 2024 at Exelixis, Inc. (EXEL)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 21
2024
|
Alan M Garber Director |
SELL
Open market or private sale
|
Direct |
19,205
-34.98%
|
$460,920
$24.01 P/Share
|
|
Mar 21
2024
|
Alan M Garber Director |
BUY
Exercise of conversion of derivative security
|
Direct |
23,491
+29.96%
|
$446,329
$19.57 P/Share
|
|
Feb 23
2024
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
47,020
-10.89%
|
$987,420
$21.45 P/Share
|
|
Feb 23
2024
|
Patrick J. Haley EVP, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
63,350
+12.79%
|
-
|
|
Feb 23
2024
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
63,350
+8.82%
|
-
|
|
Feb 23
2024
|
Christopher J. Senner EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
82,121
+9.85%
|
-
|
|
Feb 23
2024
|
Michael Morrissey President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
241,670
+18.88%
|
-
|
|
Feb 23
2024
|
Dana Aftab CSO/EVP Disc & Trans Research |
BUY
Grant, award, or other acquisition
|
Direct |
63,350
+10.46%
|
-
|
|
Feb 23
2024
|
Amy C. Peterson EVP Prod Dev & Med Aff & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
82,121
+20.31%
|
-
|
|
Feb 21
2024
|
David Edward Johnson Director |
BUY
Open market or private purchase
|
Indirect |
190,000
+14.72%
|
$3,800,000
$20.7 P/Share
|
|
Feb 15
2024
|
Dana Aftab CSO/EVP Disc & Trans Research |
SELL
Payment of exercise price or tax liability
|
Direct |
10,630
-2.17%
|
$212,600
$20.39 P/Share
|
|
Jan 11
2024
|
Dana Aftab CSO/EVP Disc & Trans Research |
SELL
Payment of exercise price or tax liability
|
Direct |
11,606
-2.32%
|
$255,332
$22.86 P/Share
|
|
Jan 11
2024
|
Dana Aftab CSO/EVP Disc & Trans Research |
BUY
Grant, award, or other acquisition
|
Direct |
63,224
+11.2%
|
-
|
|
Jan 11
2024
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
13,613
-3.56%
|
$299,486
$22.86 P/Share
|
|
Jan 11
2024
|
Patrick J. Haley EVP, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
74,462
+16.31%
|
-
|
|
Jan 11
2024
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
13,061
-2.16%
|
$287,342
$22.86 P/Share
|
|
Jan 11
2024
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
71,418
+10.56%
|
-
|
|
Jan 11
2024
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,862
-3.16%
|
$480,964
$22.86 P/Share
|
|
Jan 11
2024
|
Christopher J. Senner EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
80,186
+10.39%
|
-
|
|
Jan 11
2024
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
63,717
-7.41%
|
$1,401,774
$22.86 P/Share
|
|
Jan 11
2024
|
Michael Morrissey President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
250,374
+22.54%
|
-
|
|
Jan 05
2024
|
Mary C Beckerle Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,424
+50.0%
|
-
|
|
Jan 05
2024
|
Sue Gail Eckhardt Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,424
+50.0%
|
-
|